Piramal Pharma's $90 Million Investment to Expand US Operations Amid Rising Demand
Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635), a globally recognized leader in pharmaceuticals and wellness, has announced a major investment initiative involving $90 million aimed at expanding its operational footprint in the United States. This strategic move, which coincided with the 2025 SelectUSA Investment Summit, underscores the company's commitment to enhancing its capabilities in response to increasing demand from US customers while supporting the trend of reshoring pharmaceutical supply chains back to the USA.
The planned expansions will be executed at two of Piramal's established sites located in Lexington, Kentucky, and Riverview, Michigan. These investments reflect the company's belief in the value and advantages of innovative development within the US market. Both expansions will be financed through bank loans and internal reserves, representing an efficient and low-risk approach to ramping up production capacities in the US.
At the Lexington site, which specializes in sterile compounding, liquid filling, and lyophilization for injectable medications, the expansion will see the development of a new facility spanning 24,000 square feet, including a state-of-the-art laboratory. This facility will enable large-scale commercial production, thereby facilitating efficient scaling of clients' injectable pharmaceutical products. Noteworthy upgrades to this site will include a new filling line, two large-scale lyophilizers, a dedicated sealing machine, and an external bottle-washing system. The completion and operational rollout of this facility are expected by the end of 2027.
Meanwhile, the Riverview site, with over five decades of reputation in the development and manufacturing of active pharmaceutical ingredients (APIs) and highly potent APIs (HPAPIs), will add a commercial suite solely dedicated to the development and production of payload linkers. These highly potent substances play a crucial role in the development of antibody-drug conjugates (ADCs) and other bioconjugated therapies. This new payload-linker suite is set to be operational before the end of 2025.
The expansions at both sites are expected to foster increased opportunities for integrated projects, particularly contributing robustly to Piramal's ADC development and manufacturing initiatives under the ADCelerate™ brand. This program boasts capabilities for the development and commercial scale of monoclonal antibodies, payload linkers, conjugates, as well as the filling and finishing processes, significantly reducing project timelines to GMP drug product availability in as little as 12 months without compromising quality standards. Such capabilities reinforce Piramal's standing as a reliable global partner for the biopharmaceutical manufacturing sector.
Peter DeYoung, CEO of Piramal Global Pharma, noted, "Since its inception, Piramal Pharma Ltd. has channeled $570 million into its medication development operations in the USA. The US market is our largest, currently employing approximately 750 people. The capacity and service expansions at these two US facilities—alongside previous critical investments in our drug products facility in Sellersville, PA, and inhalational anesthetic drug products in Bethlehem, PA—will further support our clients who value our offerings in an onshore environment."
Piramal Pharma is committed to reducing patient suffering due to illnesses and strives to support its customers in developing innovative healthcare solutions. These facility enhancements mark a significant step forward in supporting key and rapidly growing segments of drug development. Payload linkers are fundamental to the creation of bioconjugates, which provide the foundation for numerous cancer therapies, while sterile filling and finishing processes represent the final phase in the production of injectable drugs. Collectively, these advancements bolster Piramal's integrated drug development and manufacturing services, ultimately leading to quicker patient access to new treatments.
Piramal Pharma Limited (PPL) operates across 17 global development and manufacturing sites with a comprehensive distribution network spanning over 100 countries. The company encompasses Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing entity, and Piramal Critical Care (PCC), which specializes in complex generics for hospitals, as well as the Consumer Healthcare segment in India that offers various wellness products. Additionally, PPL holds a strategic minority stake in Yapan Bio Private Limited, which operates in the biopharmaceuticals and vaccine sectors. Find out more at Piramal Pharma's LinkedIn.
The planned expansions will be executed at two of Piramal's established sites located in Lexington, Kentucky, and Riverview, Michigan. These investments reflect the company's belief in the value and advantages of innovative development within the US market. Both expansions will be financed through bank loans and internal reserves, representing an efficient and low-risk approach to ramping up production capacities in the US.
At the Lexington site, which specializes in sterile compounding, liquid filling, and lyophilization for injectable medications, the expansion will see the development of a new facility spanning 24,000 square feet, including a state-of-the-art laboratory. This facility will enable large-scale commercial production, thereby facilitating efficient scaling of clients' injectable pharmaceutical products. Noteworthy upgrades to this site will include a new filling line, two large-scale lyophilizers, a dedicated sealing machine, and an external bottle-washing system. The completion and operational rollout of this facility are expected by the end of 2027.
Meanwhile, the Riverview site, with over five decades of reputation in the development and manufacturing of active pharmaceutical ingredients (APIs) and highly potent APIs (HPAPIs), will add a commercial suite solely dedicated to the development and production of payload linkers. These highly potent substances play a crucial role in the development of antibody-drug conjugates (ADCs) and other bioconjugated therapies. This new payload-linker suite is set to be operational before the end of 2025.
The expansions at both sites are expected to foster increased opportunities for integrated projects, particularly contributing robustly to Piramal's ADC development and manufacturing initiatives under the ADCelerate™ brand. This program boasts capabilities for the development and commercial scale of monoclonal antibodies, payload linkers, conjugates, as well as the filling and finishing processes, significantly reducing project timelines to GMP drug product availability in as little as 12 months without compromising quality standards. Such capabilities reinforce Piramal's standing as a reliable global partner for the biopharmaceutical manufacturing sector.
Peter DeYoung, CEO of Piramal Global Pharma, noted, "Since its inception, Piramal Pharma Ltd. has channeled $570 million into its medication development operations in the USA. The US market is our largest, currently employing approximately 750 people. The capacity and service expansions at these two US facilities—alongside previous critical investments in our drug products facility in Sellersville, PA, and inhalational anesthetic drug products in Bethlehem, PA—will further support our clients who value our offerings in an onshore environment."
Piramal Pharma is committed to reducing patient suffering due to illnesses and strives to support its customers in developing innovative healthcare solutions. These facility enhancements mark a significant step forward in supporting key and rapidly growing segments of drug development. Payload linkers are fundamental to the creation of bioconjugates, which provide the foundation for numerous cancer therapies, while sterile filling and finishing processes represent the final phase in the production of injectable drugs. Collectively, these advancements bolster Piramal's integrated drug development and manufacturing services, ultimately leading to quicker patient access to new treatments.
About Piramal Pharma Limited
Piramal Pharma Limited (PPL) operates across 17 global development and manufacturing sites with a comprehensive distribution network spanning over 100 countries. The company encompasses Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing entity, and Piramal Critical Care (PCC), which specializes in complex generics for hospitals, as well as the Consumer Healthcare segment in India that offers various wellness products. Additionally, PPL holds a strategic minority stake in Yapan Bio Private Limited, which operates in the biopharmaceuticals and vaccine sectors. Find out more at Piramal Pharma's LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.